CA-TYLIN
16.3.2022 22:25:11 CET | Business Wire | Press release
T.Y. Lin International, a globally recognized full-service infrastructure consulting firm, has unveiled a new brand strategy to unify its global operations. The unified brand will connect clients more effectively with TYLin’s multi-discipline global engineering resources to solve infrastructure challenges with innovative and technically advanced solutions at the regional and local levels.
Effective immediately, the company formerly known as T.Y. Lin International will go to market as TYLin . A redesigned logo, also part of the new brand strategy, represents the concept of “Connections” which is at the heart of the TYLin brand story. As a global engineering firm, TYLin connects clients with innovative thinking and global resources to solve their most important infrastructure challenges and enhance how people, places, and communities connect.
The story behind the development of the new TYLin brand and logo can be reviewed on the company’s new website www.TYLin.com .
Historically, TYLin has been recognized for its expertise in designing iconic bridges. Over the years, the company has established itself as a global leader providing engineering services and thought leadership to all segments of the built environment, including aviation, buildings, rail and transit, roads and highways, and water, in addition to bridges. TYLin’s strategic brand positioning highlights the company’s extensive knowledge and experience across all these sectors.
“The refreshed TYLin brand builds on the legacy of innovation created by our founder, Professor Tung-Yen (T.Y.) Lin, and the long-standing relationships we have with our clients around the world,” said Matthew Cummings, PE, TYLin President and Chief Executive Officer. “The rebranding signals our renewed commitment to connect our clients with the technical expertise, innovative thinking, and resources they need so that together we can continue to elevate the lives of people in the communities we serve. It will also foster unity within our firm, streamlining the processes for our employees to connect and collaborate with their global colleagues.”
The new TYLin brand is based on three key pillars: Approachable People who understand clients’ objectives and collaborate to provide seamless delivery of technological solutions through a lifecycle approach; Proven Capabilities and technical excellence; and access to Global Experience with innovative designs in advanced mobility infrastructure, smart buildings, and sustainable water solutions.
Since 1989, TYLin has been part of Dar Group , an international network of professional services firms comprising more than 17,000 staff in over 100 countries. TYLin, the lead brand within Dar’s Global Infrastructure (GI) Pillar, has 3,200 employees in 11 countries.
The strategy to unify the TYLin global brand is part of a phased, multi-year approach that will more closely align all TYLin offices and GI Pillar companies worldwide and facilitate access to global resources to support clients and provide enhanced career development opportunities for employees.
About TYLin:
Founded in 1954, TYLin is a globally recognized, full-service infrastructure consulting firm committed to providing innovative, cost-effective, constructible designs for the global infrastructure market. With 3,200 employees working in 65 offices throughout the Americas, Asia, and Europe, the firm provides support on projects of varying size and complexity. TYLin is a member of Dar Group, a global, privately-owned professional services group, and its industry-leading family of Global Infrastructure companies. For more information about the company, please visit www.tylin.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316006051/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
